Mycosis fungoides (MF) is characterized by patches that develop over time into infiltrated plaques, and eventually into tumors.17 In some patients with advanced disease, lymphadenopathy and involvement of internal organs develops.17 Initial MF lesions have a propensity to affect sun-protected areas such as the buttocks.17
Sézary syndrome (SS) is characterized by erythroderma, and can include edema, marked exfoliation, and lichenification. Lesions may be intensely pruritic. Lymphadenopathy, onychodystrophy, alopecia, and palmoplantar hyperkeratosis are also common features.17
Patch CTCL
Plaque CTCL
Tumor phase of CTCL
Specially designed for medical professionals to use in their practice.
Sherry's Experience
The Caregiver's Perspective
The Long Journey
About THERAKOS™ Photopheresis Treatment
How THERAKOS™ Photopheresis Works
See top Opinion Leaders address FAQs about THERAKOS™ Photopheresis
Indications
Methoxsalen Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.
Methoxsalen should be used only by physicians who have special training in the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis Systems. Methoxsalen is contraindicated in patients exhibiting idiosyncratic reactions to psoralen compounds, patients with a specific history of a light sensitive disease, or patients with aphakia.
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate extracorporeal volume loss or shifts, or patients with coagulation disorders. See Important Safety Information for additional details.
